CoChat

Glutamatergic synapses in neurodevelopmental disorders

Moretto, Edoardo, Murru, Luca, Martano, Giuseppe, Sassone, Jenny, Passafaro, Maria · 2018 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
Cited by 136

The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.

Abstract

Neurodevelopmental disorders (NDDs) are a group of diseases whose symptoms arise during childhood or adolescence and that impact several higher cognitive functions such as learning, sociability and mood. Accruing evidence suggests that a shared pathogenic mechanism underlying these diseases is the dysfunction of glutamatergic synapses. We summarize present knowledge on autism spectrum disorders (ASD), intellectual disability (ID), Down syndrome (DS), Rett syndrome (RS) and attention‐deficit hyperactivity disorder (ADHD), highlighting the involvement of glutamatergic synapses and receptors in these disorders. The most commonly shared defects involve &agr;‐amino‐3‐hydroxy‐5‐methyl‐ 4‐isoxazole propionic acid receptors (AMPARs), N‐methyl‐d‐aspartate receptors (NMDARs) and metabotropic glutamate receptors (mGluRs), whose functions are strongly linked to synaptic plasticity, affecting both cell‐autonomous features as well as circuit formation. Moreover, the major scaffolding proteins and, thus, the general structure of the synapse are often deregulated in neurodevelopmental disorders, which is not surprising considering their crucial role in the regulation of glutamate receptor positioning and functioning. This convergence of defects supports the definition of neurodevelopmental disorders as a continuum of pathological manifestations, suggesting that glutamatergic synapses could be a therapeutic target to ameliorate patient symptomatology. Graphical abstract Core mechanisms involved in the pathogenesis of NDDs. ASD (Autism Spectrum Disorder): Neurexin and neuroligins are transmembrane proteins localised in the pre‐ and post‐synaptic compartments, respectively that interact each other in the synaptic cleft. Mutations in the gene encoding Neurexin‐1, Neuroligin‐3 and 4 have been found in patients affected by ASD. Neurexins regulate presynaptic vesicles release whereas neuroligins, through the interaction with PSD‐95, affect NMDARs functioning. SHANK3 protein belongs to a class of scaffolding molecules and it is implicated in autistic phenotype in patients affected by Phelan McDermid syndrome. This protein regulates different glutamate receptors (NMDARs, AMPARs and mGluR5) through direct or indirect interactions mediated by PSD‐95, SAPAP and Homer. Moreover, IGF‐1 pathway has been found associated to Shank3‐depletion defects. Mutations on the NMDARs subunit encoding genes GRIN2A and GRIN2B, are also directly affected by mutations in ASDs patients. ID (Intellectual Disability): FMRP protein, encoded by FMR1 gene, which mutations cause Fragile X syndrome, regulates mRNA translation of a great variety of proteins with crucial functions in excitatory post‐synapses such as STEP, PSD‐95 and APP. mGluR5 is strongly implicated in the regulation of FMRP functioning, and vice versa. OPHN1 and TSPAN7, which encoding genes are found mutated in patients affected by ID, are involved in the regulation of AMPARs trafficking. The MAGUK protein CASK, also affected in ID patients, has functions in both the pre and post‐synaptic compartments. In the first case it regulates Voltage Gated Calcium Channels (VGCC) and Neurexins; in the second it is implicated in NMDARs trafficking similarly to SAP102, another protein which encoding gene has been found mutated in ID patients. The presynaptic proteins Synaptophysin (SYP) and Synapsin (SYN) are both strongly implicated in the release of presynaptic vesicles containing the neurotransmitter glutamate and mutations in their coding genes have been linked to ID. DS (Down Syndrome): In DS patients the triplication of Chromosome 21 leads to different defects. The gene encoding for APP is localized in Chr 21 and its overexpression results in an Alzheimer‐like dementia. Nine genes contained in the chromosome 21 encode for proteins that interact with NMDARs directly or through the Calcineurin/Calmodulin (CaN/CaM) system. Moreover, neuronal and glial alterations in metabotropic glutamate receptors have been identified. RS (Rett Syndrome): MeCP2 protein is an epigenetic modulator. Studies on its function have elucidated its regulatory effect on PSD‐95, which appears to be reduced upon MeCP2 loss of function, and on GluA1‐containing AMPARs, which instead are increased. mGluRs have also been involved in RS; in particular, mGluR5‐dependent LTD has been found impaired in Mecp2 knock‐out mice. ADHD (Attention‐deficit hyperactivity disorder): ADHD is probably the most complex of NDDs with very little knowledge on specific mechanisms involving glutamate. Nowadays, several mutations on genes encoding for NMDARs subunits, GRIN2A and GRIN2B, and for mGluRs, GRM1, GRM5, GRM7 and GRM8, have been linked to this pathology. Figure. No caption available. HighlightsGlutamatergic synapse defects are common features in ASD, ID, DS, RS and ADHD.Shared NDDs pathological mechanisms converge on NMDARs and mGluRs.Different NDDs could be treated with similar therapeutic approaches.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pnpbp.2017.09.014

Cites

101 of 101 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 101 references

Cited by

See all 136

Metadata

Authors
Moretto, E., Murru, L., Martano, G., Sassone, J., & Passafaro, M.
Venue
Progress in Neuro-Psychopharmacology and Biological Psychiatry
Publisher
Elsevier BV
Published
2018-06
Volume
84
Issue
Pt B
Pages
328-342
ISSN
0278-5846 (ISSN-L)
OpenAlex
W2754148882
Cited by
136
References
101
FWCI
3.99
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glutamatergic synapses in neurodevelopmental disorders. https://app.cochat.ai/papers/10.1016/j.pnpbp.2017.09.014
The paper
Moretto, E., Murru, L., Martano, G., Sassone, J., & Passafaro, M. (2018). Glutamatergic synapses in neurodevelopmental disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry. https://doi.org/10.1016/j.pnpbp.2017.09.014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.